SCHEDULE 13G/A: Nantahala Capital Boosts Unicycive Therapeutics Stake to 9.99%

Nantahala Capital Management and its managing members have reported an increased beneficial ownership of 9.99% in Unicycive Therapeutics, including shares from warrants.

Summary

• Nantahala Capital Management, LLC, along with Wilmot B. Harkey and Daniel Mack, collectively reported beneficial ownership of 1,234,596 shares of Unicycive Therapeutics, Inc. common stock.
• This represents 9.99% of the company's outstanding common stock as of June 30, 2025.
• The reported ownership includes 295,394 shares that may be acquired within sixty days through the exercise of warrants.
• The reporting persons share both voting and dispositive power over all 1,234,596 shares.
• BLACKWELL PARTNERS LLC SERIES A, a fund advised by Nantahala, has the right to receive or direct dividends or proceeds from the sale of more than five percent of the outstanding common stock beneficially owned by Nantahala.

Sentiment

Score: 7

Explanation: The filing indicates a significant beneficial ownership stake by an investment management firm, which can be interpreted as a vote of confidence in the issuer. The inclusion of warrants suggests a potential for further commitment.

Positives

• Increased institutional ownership by Nantahala Capital Management, a recognized investment adviser, signals confidence in Unicycive Therapeutics.
• The inclusion of exercisable warrants suggests a potential future increase in direct equity holdings by the reporting persons.

Future Outlook

NA

Management Comments

• Reporting persons certified that the securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of Unicycive Therapeutics, Inc.

Industry Context

This filing indicates an increased stake by an investment firm in Unicycive Therapeutics. Without further information on Unicycive's specific industry or recent performance, it is difficult to provide detailed industry context. However, increased institutional investment can be a positive signal within any industry, suggesting investor confidence.

Stakeholder Impact

• Shareholders: Increased institutional ownership may enhance market confidence and liquidity.
• Potential for future dilution if warrants are exercised, though this is already factored into the beneficial ownership percentage.

Key Dates

Recommendation

The filing indicates a substantial beneficial ownership stake by Nantahala Capital Management, including shares from exercisable warrants, which suggests a positive long-term view from a sophisticated investor. However, this Schedule 13G filing provides no operational or financial performance details of Unicycive Therapeutics, Inc. to justify a stronger recommendation. Investors should consider this as a positive signal but await further fundamental analysis before making definitive investment decisions.

Keywords

Unicycive Therapeutics, Nantahala Capital Management, Schedule 13G, beneficial ownership, common stock, institutional investment, warrants, equity stake